Thus, the combination of BTK and MALT1 inhibitors apparently additively increases the efficacy over single agent treatment to suppress expression of NF-κB dependent pro-survival proteins in ABC DLBCL cells. Here, BTK is linked to diffuse large B-cell lymphoma.